Hormone Refractory Prostate Cancer (HRPCA) Market Size & Share, Application (Hospitals, Specialty Clinics, Ambulatory Surgical Centers); Treatment Type - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Hormone Refractory Prostate Cancer Industry - Regional Synopsis

North America Market Statistics   

North America hormone refractory prostate cancer market is predicted to capture revenue share of over 41.7% by 2037. With continuous research to find biomarkers for response to current treatments and possible novel therapeutic targets, personalized therapy has enormous promise in HRPC within the region. Furthermore, prominent players are focusing on personalized medicine to save costs by directing resources toward therapies that have the best chance of succeeding, in improving patient outcomes.

The U.S. market is growing exponentially owing to the smooth regulatory approvals and procedures to push the growth of novel drug developments. For instance, in March 2025, to enable its use earlier in therapy, the U.S. FDA has extended the approval of 177Lu-PSMA-617 (Pluvicto). The treatment makes use of a molecule known as PSMA (prostate-specific membrane antigen), which specifically seeks for and binds to a certain protein on the surface of cancer cells. It emits radiation that kills the cancer cell and ruins DNA.

Canada hormone refractory prostate cancer market is likely to witness substantial growth during the forecast period attributed to the support from regulatory authorities in restricting the growth of cancer cases within the country. For instance, in November 2024, to improve statistics to guide breast cancer screening practices in Canada, the Canadian Partnership for Tomorrow's Health received USD 295,000 to probe into racial and ethnic variations in breast cancer screening participation, cancer treatments, and outcomes.

Asia Pacific Market Analysis

The hormone refractory prostate cancer (HRPCA) market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline. The growth can be attributed to the increased demand for better healthcare treatment options fueled by rising disposable income. It further reflects a growing need for a higher quality of life. Additionally, rising educational attainment levels raise awareness of cancer types and suitable treatments is projected to propel the market growth during the stipulated timeframe.

India market is experiencing robust growth due to the local governments conducive support. For instance, in February 2025, the ICMR's National Cancer Registry Programme (NCRP) helps make evidence-based policy decisions by gathering and analysing the data. In addition, India established the Quad Cancer Moonshot in September 2024 with the goal of eradicating cervical cancer throughout the Indo-Pacific region in collaboration with the US, Australia, and Japan. It guaranteed early detection, efficient treatment, and increased survival rates. This effort seeks to expand screening and immunization programs, promote state-of-the-art research, and fortify international cooperation.

China market is exponentially scaling owing to the imperative initiatives taken by the local government to promote health and wellness. For instance, it was published by the National Library of Medicine that China's national strategy, Healthy China 2030, emphasizes the significance of China's commitment to the United Nations' 2030 Agenda for Sustainable Development. The government played an active participation in global health governance, and the importance of making people's health a developmental priority.